Investigational drugs for the treatment of dysmenorrhea.
Anti-inflammatories
dysmenorrhea
endometriosis
hormonal therapy
medical therapy
Journal
Expert opinion on investigational drugs
ISSN: 1744-7658
Titre abrégé: Expert Opin Investig Drugs
Pays: England
ID NLM: 9434197
Informations de publication
Date de publication:
19 Mar 2024
19 Mar 2024
Historique:
pubmed:
4
3
2024
medline:
4
3
2024
entrez:
4
3
2024
Statut:
aheadofprint
Résumé
Dysmenorrhea is the most common cause of gynecological pain among women that has considerable impact on quality of life and psychosocial wellbeing. Non-steroidal anti-inflammatory drugs (NSAIDs) and hormonal therapies are most commonly used to treat dysmenorrhea. However, given these drugs are often associated with bothersome side effects and are less effective when there is an underlying cause contributing to dysmenorrhea (e.g. endometriosis), a patient-centered approach to managing dysmenorrhea is important. Various new drugs are currently being investigated for the treatment of primary and secondary dysmenorrhea. This review provides an updated overview on new therapeutic targets and investigational drugs for the treatment of primary and secondary dysmenorrhea. The authors describe the clinical development and implications of these drugs. Among the investigative drugs discussed in this review, anti-inflammatories show the most promising results for the treatment of dysmenorrhea. However, given some trials have considerable methodological limitations, many drugs cannot be currently recommended. Research focused on understanding the mechanisms involved in menstruation and its associated symptoms will be important to identify new therapeutic targets for dysmenorrhea. Further robust clinical trials are required to better understand the efficacy and safety of investigational drugs for treating primary and secondary dysmenorrhea.
Identifiants
pubmed: 38436301
doi: 10.1080/13543784.2024.2326627
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM